Inclusion Criteria:

- Informed consent

- Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any
prior chemotherapy received

- HER-2 overexpression 2+ or 3+ using IHC or FISH +

- Measurable disease

- At least one prior chemotherapy regimen

- Not in a prior irradiation field

- No patients with brain metastatic disease who has not been irradiated or uncontrolled
brain metastatic disease after irradiation

- No more than 25% of myeloproductive bone marrow irradiated. More than 4 weeks since
prior radiotherapy and recovered

- Age 18 - 75 year old

- Performance status (WHO) 0-2

- Life expectancy more than 12 weeks

- Absolute neutrophil count > 1500/mm^3, platelet count > 100000/mm^3, hemoglobin > 9
gr/mm^3)

- Adequate liver (bilirubin < 2 mg/dL, SGOT/SGPT < 2 times upper limit of normal, ALP <
3 times upper limit of normal, creatinine < 1.5 upper limit of normal

- Adequate cardiac function (LVEF > 50%)

Exclusion Criteria:

- Pregnant or nursing

- Positive pregnancy test

- Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce
P-450 cytochrome

- Motor or sensory neuropathy > grade 1 according to NCIC toxicity criteria

- History of allergic reaction attributed to docetaxel

- Psychiatric illness or social situation that would preclude study compliance

- Other concurrent uncontrolled illness

- Other invasive malignancy within the past 5 years except cured basal cell skin
carcinoma and cervical carcinoma in situ